Haichao Zhang
Harbin Medical University(CN)State Intellectual Property Office(CN)Jiangsu T-mab BioPharma (China)(CN)PowerChina (China)(CN)Heilongjiang Provincial Hospital(CN)Education Department of Heilongjiang Province(CN)Guizhou Electric Power Design and Research Institute(CN)First Affiliated Hospital of Harbin Medical University(CN)Matrix Research (United States)(US)System Equipment (China)(CN)
Publications by Year
Research Areas
Cell death mechanisms and regulation, RNA Interference and Gene Delivery, Cancer therapeutics and mechanisms, Synthesis and Characterization of Heterocyclic Compounds, Bioactive Compounds and Antitumor Agents
Most-Cited Works
- → An inhibitor of Bcl-2 family proteins induces regression of solid tumours(2005)3,369 cited
- → ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets(2013)2,976 cited
- → ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor(2008)1,942 cited
- → Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy(2015)535 cited
- → Rationale for Bcl‐XL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies(2000)388 cited
- → Distinctive Roles of PHAP Proteins and Prothymosin-α in a Death Regulatory Pathway(2003)372 cited